

ARTICLE OPEN



Characteristics of discordance between amyloid positron emission tomography and plasma amyloid- β 42/40 positivity

Jung-Min Pyun¹, Young Ho Park², Young Chul Youn³, Min Ju Kang⁴, Kyu Hwan Shim⁵, Jae-Won Jang⁶, Jihwan You¹, Kwangsik Nho^{7,8}, SangYun Kim² and the Alzheimer's Disease Neuroimaging Initiative*

© The Author(s) 2024

Various plasma biomarkers for amyloid- β (A β) have shown high predictability of amyloid PET positivity. However, the characteristics of discordance between amyloid PET and plasma A β 42/40 positivity are poorly understood. Thorough interpretation of discordant cases is vital as A β plasma biomarker is imminent to integrate into clinical guidelines. We aimed to determine the characteristics of discordant groups between amyloid PET and plasma A β 42/40 positivity, and inter-assays variability depending on plasma assays. We compared tau burden measured by PET, brain volume assessed by MRI, cross-sectional cognitive function, longitudinal cognitive decline and polygenic risk score (PRS) between PET/plasma groups (PET-/plasma-, PET-/plasma+, PET+/plasma-, PET+/plasma+) using Alzheimer's Disease Neuroimaging Initiative database. Additionally, we investigated inter-assays variability between immunoprecipitation followed by mass spectrometry method developed at Washington University (IP-MS-WashU) and Elecsys immunoassay from Roche (IA-Elc). PET+/plasma+ was significantly associated with higher tau burden assessed by PET in entorhinal, Braak III/IV, and Braak V/VI regions, and with decreased volume of hippocampal and precuneus regions compared to PET-/plasma-. PET+/plasma+ showed poor performances in global cognition, memory, executive and daily-life function, and rapid cognitive decline. PET+/plasma+ was related to high PRS. The PET-/plasma+ showed intermediate changes between PET-/plasma- and PET+/plasma+ in terms of tau burden, hippocampal and precuneus volume, cross-sectional and longitudinal cognition, and PRS. PET+/plasma- represented heterogeneous characteristics with most prominent variability depending on plasma assays. Moreover, IP-MS-WashU showed more linear association between amyloid PET standardized uptake value ratio and plasma A β 42/40 than IA-Elc. IA-Elc showed more plasma A β 42/40 positivity in the amyloid PET-negative stage than IP-MS-WashU. Characteristics of PET-/plasma+ support plasma biomarkers as early biomarker of amyloidopathy prior to amyloid PET. Various plasma biomarker assays might be applied distinctively to detect different target subjects or disease stages.

Translational Psychiatry (2024)14:88; <https://doi.org/10.1038/s41398-024-02766-6>

INTRODUCTION

Alzheimer's disease (AD) is characterized by pathological hallmarks with amyloidopathy and tauopathy leading to neuronal degeneration with cognitive impairment [1]. Amyloid pathology as the early change of AD, can be evaluated by amyloid plaque detection using amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) amyloid- β (A β) concentration measurement via a CSF study [1]. Several assays measuring plasma A β have been developed and showed promising performance to predict amyloid PET positivity [2, 3]. These plasma A β biomarkers have been validated in diverse cohorts and clinical use is expected, owing to cost advantages and practical value [4].

Plasma A β biomarker performance has often been assessed by the concordance rate with amyloid PET finding, which has been used as a gold standard biomarker for central amyloidopathy. Although plasma biomarkers have been optimized reaching high concordance rate, discordant cases between amyloid PET and plasma A β are needed to be understood regarding their characteristics. Discordance could originate from differences in detection target between PET and plasma biomarker and technical limitation of plasma assay. Discordant groups could also represent different disease stages, or presence of concomitant mixed pathology than concordant group. Inter-assay variability can also be considered. There are various assays to measure plasma A β with different methodologies [2]. Exploring whether

¹Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, 59, Daesagwan-ro, Yongsan-gu, Seoul 04401, Republic of Korea. ²Department of Neurology, Seoul National University Bundang Hospital and Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Republic of Korea. ³Department of Neurology, Chung-Ang University Hospital, 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Republic of Korea. ⁴Department of Neurology, Veterans Health Service Medical Center, 53, Jinhwangdo-ro 61-gil, Gangdong-gu, Seoul 05368, Republic of Korea. ⁵Department of Bionano Technology, Gachon University, 1342, Seongnamdaero, Sujeong-gu, Seongnam-si, Gyeonggi-do 13120, Republic of Korea. ⁶Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, 156, Baengnyeong-ro, Chuncheon-si, Gangwon-do 24289, Republic of Korea. ⁷Department of Radiology and Imaging Sciences, and the Indiana Alzheimer Disease Center, Indiana University School of Medicine, 355 W 16th, GH 4101, Indianapolis, IN 46202, USA. ⁸Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, 410 W 10th, Health Information and Translational Science Building, Suite 5000, Indianapolis, IN 46202, USA. *A list of authors and their affiliations appears at the end of the paper. ✉email: neuroksy@snu.ac.kr

Received: 2 August 2023 Revised: 8 January 2024 Accepted: 10 January 2024

Published online: 10 February 2024

discordant group in an assay is also discordant in another can help understand the group feature. As plasma biomarker $\text{A}\beta$ is imminent to integration into clinical guidelines, proper interpretation of discordant case is important. To the best of our knowledge, no prior studies have explored the discordant cases.

This study aimed to investigate the characteristics of concordant and discordant groups between PET and plasma amyloid positivity (PET−/plasma−, PET−/plasma+, PET+/plasma−, PET+/plasma+). We compared tau burden measured by PET, brain volume assessed by magnetic resonance imaging (MRI), cross-sectional cognitive function, longitudinal cognitive decline, and polygenic risk score (PRS) between PET/plasma groups. We also compared the characteristics of groups classified by two different plasma assays. A β 42/40 level measurement of identical samples by various plasma assays were used from Alzheimer's Disease Neuroimaging Initiative (ADNI) database. We included two assays, immunoprecipitation followed by mass spectrometry (IP-MS) method developed at Washington University (IP-MS-WashU) and Elecsys immunoassay from Roche Diagnostics (IA-Elc), which showed the most promising amyloid PET predictability among IP-MS assays and immunoassays in previous head-to-head comparison study [3].

MATERIALS AND METHODS

Participants

We obtained data from the ADNI database (<http://adni.loni.usc.edu>). ADNI launched in 2003 as a public-private partnership, primarily aims to test whether neuroimaging, other biological markers, and clinical neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. Written informed consent was obtained at the time of enrollment and included permission for analysis and data sharing. The protocol and informed consent forms were approved by the institutional review boards at each of the participating institution.

Here, we included participants based on the availability of amyloid PET and plasma A β 42/40 profiles by two different assays, IP-MS-WashU and IA-Elc. Duplicate plasma measurements ($n=9$) were excluded from both assays, and one sample with failed quality check was excluded from IP-MS-WashU. For analyses, we used 120 participants from IP-MS-WashU and 121 participants from IA-Elc.

Neuroimaging

Amyloid imaging was acquired using [^{18}F]florbetapir PET in four 5 min frames 50–70 min post injection of 10 mCi and spatially normalized to the statistical parametric mapping (SPM) template using SPM8 (Wellcome Trust Center for Neuroimaging, UCL, UK) in MATLAB R2013a (Mathworks, Natick, MA). Additional details of data processing are available online (<http://adni.info.org>). Standardized uptake value ratio (SUVR), summary value of florbetapir retention, was determined using the global cortical target region of interest (ROI) with the cerebellum reference regions [5]. Amyloid PET positivity was defined as $\text{SUVR} \geq 1.11$ [6].

Tau imaging using Flortaucipir (FTP) PET was performed and co-registered to the MRI closest to the tau visit. The FTP SUVR was generated using inferior cerebellum gray matter as a reference region. We used composite Braak ROIs for the analysis, which approximate tau spreading in the anatomical Braak stages [7], Braak1 (entorhinal), Braak III/IV (III: parahippocampal, fusiform, lingual, and amygdala regions/ IV: middle temporal, caudal anterior cingulate, rostral anterior cingulate, posterior cingulate, isthmus cingulate, insula, inferior temporal, and temporal pole regions), and Braak V/VI (V: superior frontal, lateral orbitofrontal, medial orbitofrontal, frontal pole, caudal middle frontal, rostral middle frontal, pars opercularis, pars orbitalis, pars triangularis, lateral occipital, parietal supramarginal, parietal inferior, superior temporal, parietal superior, precuneus, bank of superior temporal sulcus, and transverse temporal regions/ VI: pericalcarine, postcentral, cuneus, precentral, and paracentral regions). Braak2 (hippocampus) was not included, since this region can be contaminated by off-target binding in the choroid plexus.

Structural brain volume was estimated from T1-weighted brain MRI scans using FreeSurfer (surfer.nmr.mgh.harvard.edu) [8]. ROIs of temporal and parietal regions including parahippocampus, hippocampus, precuneus, superior parietal, and inferior parietal lobes were adjusted for the

estimated intracranial volume. More details regarding neuroimaging processing are available online (<http://adni.info.org>).

Plasma A β 42/40

ADNI blood sample were collected in two 10 mL EDTA tubes and centrifuged at room temperature within 1 h of collection. After centrifugation for 15 min at 1300 rpm, plasma samples were frozen and shipped to the Biomarker Core Laboratory. More details are available online (<http://adni.info.org>).

Plasma concentrations of A β 42 and A β 40 were analyzed using IP-MS-WashU and IA-Elc between December 2020 and March 2021. The optimal value of plasma A β 42/40 to differentiate amyloid PET positivity was estimated among ADNI subjects based on the Youden index, using receiver operating characteristics (ROC) analysis (eFig. 1 in Supplement 1). The cutoffs were 0.1279 for IP-MS-WashU with area under the curve (AUC) value of 0.807 (95% confidence interval (CI) 0.726–0.888) and 0.1683 for IA-Elc with AUC value of 0.731 (95% CI 0.641–0.822). Plasma amyloid positivity was defined as $\text{A}\beta$ 42/40 \leq 0.1279 for IP-MS-WashU and $\text{A}\beta$ 42/40 \leq 0.1683 for IA-Elc.

Cognition

Cognitive function was evaluated using Mini-Mental State Exam (MMSE) [9], Clinical Dementia Rating (CDR) [10], CDR Sum of Boxes (CDR SB), composite score of memory (ADNI MEM) [11] and executive function (ADNI EF) [12].

PRS calculation

PRSs were calculated using the software PRSice v2.3.1.e [13]. The genome-wide association studies summary statistics from Jansen et al. were used as a base dataset [14] and the phase 3 genetic data from the 1000 Genomes Project [15] for non-Hispanic participants of European ancestry were used to calculate linkage disequilibrium structure. We used a p -value threshold of 1×10^{-5} to select AD-associated single nucleotide polymorphisms (SNPs). A total of 204 SNPs are used for PRS calculation. Furthermore, PRS was z -transformed based on the PRS distribution of amyloid PET-negative cognitively normal participants from the ADNI cohort.

Statistical analyses

We classified participants into four groups according to PET and plasma amyloid positivity (PET−/plasma−, PET−/plasma+, PET+/plasma−, PET+/plasma+). Demographics between groups were compared using Kruskal-Wallis tests for continuous variables and chi-square tests for categorical variables. For multiple comparison correction a false discovery rate (FDR) of 0.05 using Benjamini-Hochberg procedure was used.

The distribution and concordance status of IP-MS-WashU and IA-Elc are displayed in scatterplots. To compare distribution between assays, plasma A β 42/40 values were standardized to z -scores. Association between amyloid PET SUVR and plasma A β 42/40 z -scores were depicted using smoothing spline curves. Concordance between IP-MS-WashU and IA-Elc were measured using Kendall's tau-b correlation coefficient.

We performed association analyses of the PET/plasma groups with tau PET, brain MRI volumes, cross-sectional cognitive performances, and PRS using general linear model. Age and sex were adjusted in each model. Additionally, MRI field strength was adjusted in the analysis of brain MRI volume, and educational levels in the analysis of cognitive performance.

We performed association analysis between groups and longitudinal cognitive declines using linear mixed models adjusted for age, sex, and education levels. The variable of interest was the interaction of time and groups. The dependent variable was cognitive performance with the fixed effects being age, sex, and education levels and the random effect being subject.

We used the R software (version 4.1.3) for all analyses and statistical significance was set at $p < 0.05$. The R codes used in the study are available from the corresponding author upon reasonable request.

RESULTS

Demographics of PET/plasma groups

Demographics of PET/plasma groups in both IP-MS-WashU and IA-Elc are shown in Table 1. In IP-MS-WashU, the majority was PET+/plasma+ (40.8%) followed by PET−/plasma− (37.5%). Among discordant groups (21.6%), PET−/plasma+ (13.3%) was larger than

Table 1. Demographics of study participants.

	IP-MS-WashU (n = 120)				IA-Elc (n = 121)			
	PET+/plasma-	PET-/plasma+	PET+/plasma-	PET-/plasma+	PET+/plasma-	PET-/plasma+	PET+/plasma-	PET-/plasma+
No. (%)	45 (38)	16 (13)	10 (8)	49 (41)	35 (29)	8 (7)	27 (22)	51 (42)
Age, y	75 (72, 81)	77.5 (71, 79)	80 (77, 82)	79 (75, 84)	76 (72, 81)	76 (74, 80)	77 (71, 80)	80 (75, 83)
Male (%)	22 (49)	13 (81)	5 (50)	29 (59)	19 (54)	4 (50)	17 (63)	30 (59)
Education, y	18 (14, 18)	18 (15.5, 19)	18 (16, 18)	16 (12, 20)	18 (16, 19)	15 (14, 18)	16 (14, 18)	16 (13, 18)
APOE ε4 carrier (%)	11 (24)	8 (50)	3 (30)	26 (53)	10 (29)	4 (50)	10 (37)	25 (49)
Time interval between PET and plasma, d	0 (-7.5, 2)	0 (-18, 2.5)	0 (-8, 1)	0 (-6, 4.5)	0 (-7.5, 2)	0 (-8, 1)	0 (-18, 2.5)	0 (-6, 4.5)
Plasma Aβ42/40	0.14 (0.13, 0.14)	0.12 (0.12, 0.12)	0.13 (0.13, 0.14)	0.12 (0.12, 0.12)	0.18 (0.17, 0.19)	0.15 (0.14, 0.16)	0.15 (0.14, 0.16)	0.15 (0.14, 0.16)
Amyloid PET SUVR	0.98 (0.91, 1.02)	1.02 (0.98, 1.06)	1.23 (1.16, 1.38)	1.33 (1.28, 1.47)	0.97 (0.93, 1.05)	1.01 (0.96, 1.02)	1.22 (1.15, 1.44)	1.33 (1.25, 1.46)

Abbreviations: Aβ amyloid-β, IA-Elc Elcysy immunooassay from Roche Diagnostics, IP-MS-WashU immunoprecipitation followed by mass spectrometry method developed at Washington, IQR interquartile range, PET positron emission tomography, SUVR standardized uptake value ratio.

Data are shown as median (IQR) unless otherwise specified.

Post-hoc analysis:

^aAPOE ε4 carrier: PET-/plasma- < PET+/plasma+: odds ratio = 3.44 [95% CI: 1.33–9.37], $p = 0.036$.

^bPlasma Aβ42/40: PET-/plasma- < PET+/plasma+: $Z = 5.746$, $p < 0.001$, PET-/plasma+ < PET+/plasma-: $Z = -3.89$, $p < 0.001$, PET-/plasma- < PET+/plasma+: $Z = 8.596$, $p < 0.001$, PET+/plasma- < PET+/plasma+: $Z = 4.72$, $p < 0.001$.

^cAmyloid PET SUVR: PET-/plasma- < PET+/plasma-: $Z = -4.277$, $p < 0.001$, PET-/plasma+ < PET+/plasma-: $Z = -2.997$, $p = 0.004$, PET-/plasma- < PET+/plasma+: $Z = -9.020$, $p < 0.001$, PET+/plasma- < PET+/plasma+: $Z = -5.470$, $p < 0.001$.

^dPlasma Aβ42/40: PET-/plasma- < PET+/plasma-: $Z = 6.670$, $p < 0.001$, PET-/plasma+ < PET+/plasma-: $Z = -3.961$, $p < 0.001$, PET-/plasma- < PET+/plasma+: $Z = 8.045$, $p < 0.001$, PET+/plasma- < PET+/plasma+: $Z = 4.344$, $p < 0.001$.

^eAmyloid PET SUVR: PET-/plasma- < PET+/plasma-: $Z = -3.988$, $p < 0.001$, PET-/plasma+ < PET+/plasma-: $Z = -3.708$, $p < 0.001$, PET-/plasma- < PET+/plasma+: $Z = -8.135$, $p < 0.001$, PET+/plasma- < PET+/plasma+: $Z = -7.208$, $p < 0.001$.

PET+/plasma- (8.3%). In IA-Elc, PET+/plasma+ was the majority (42.1%), followed by PET-/plasma- (28.9%). Discordant groups (28.9%) comprised larger PET-/plasma+ (22.3%) and smaller PET+/plasma- (6.6%).

Both assays showed similar sex ratio, education levels, and same time interval between PET and plasma assessment. In IP-MS-WashU, PET+/plasma+ showed greater proportion of APOE ε4 carrier than PET-/plasma-. In IA-Elc, age was significantly different across the PET/plasma groups.

Disagreement between IP-MS-WashU and IA-Elc

Distribution and concordance status of PET/plasma groups in IP-MS-WashU and IA-Elc are depicted in scatterplots (Fig. 1A, B). Plasma Aβ42/40 z-scores between IP-MS-WashU and IA-Elc were compared using smoothing spline curves, according to amyloid PET SUVR (Fig. 1C). Compared to IA-Elc, IP-MS-WashU showed more linear association between amyloid PET SUVR and plasma Aβ42/40 z-scores. In the amyloid-negative PET status, IA-Elc revealed plasma amyloid abnormality prior to IP-MS-WashU. The number of concordant and discordant cases between IP-MS-WashU and IA-Elc are presented in Fig. 1D. Kendall's tau-b correlation coefficient between IP-MS-WashU and IA-Elc was 0.796 ($p < 0.001$). The highest agreement rate between IP-MS-WashU and IA-Elc was PET+/plasma+ and the highest disagreement rate between assays was observed in PET+/plasma- (IP-MS-WashU: 80%, IA-Elc: 75%).

Association between PET/plasma groups and tau burden

PET+/plasma+ was significantly associated with higher tau PET uptake in entorhinal (IP-MS-WashU: estimate = 0.247, $p < 0.001$, IA-Elc: estimate = 0.266, $p < 0.001$), Braak III/IV (IP-MS-WashU: estimate = 0.145, $p < 0.001$, IA-Elc: estimate = 0.148, $p < 0.001$), and Braak V/VI regions (IP-MS-WashU: estimate = 0.091, $p = 0.005$, IA-Elc: estimate = 0.098, $p = 0.002$) in both assays compared to PET-/plasma- as a reference group (Fig. 2). In IP-MS-WashU, PET+/plasma- presented a significantly higher tau burden in entorhinal (estimate = 0.19, $p = 0.004$), Braak III/IV (estimate = 0.115, $p = 0.035$), and Braak V/VI regions (estimate = 0.102, $p = 0.031$) compared to PET-/plasma-. Overall, median SUVR values showed ascending tendency in the order of PET-/plasma-, PET-/plasma+, and PET+/plasma+. In contrast, PET+/plasma- revealed higher median SUVR value in Braak V/VI regions than even PET+/plasma+ (eTable 1 in Supplement 1).

Association between PET/plasma groups and brain volume

The association analyses of PET/plasma groups with brain volume included a comparison of parahippocampal, hippocampal, precuneus, supraparietal, and infraparietal regions as measured by MRI (eTable 2 in Supplement 1). Among the regions, hippocampus and precuneus showed consistent differences between groups in both assays. PET+/plasma+ showed a significantly low volume in the right (IP-MS-WashU: estimate = -0.236, $p = 0.007$, IA-Elc: estimate = -0.196, $p = 0.036$) and left (IP-MS-WashU: estimate = -0.188, $p = 0.03$, IA-Elc: estimate = -0.223, $p = 0.015$) hippocampus compared to PET-/plasma- in both assays (Fig. 3). In IA-Elc, PET+/plasma- also presented significant atrophy in right hippocampus (estimate = -0.341, $p = 0.038$) compared to PET-/plasma-. Precuneus region, which is part of AD-related parietal lobe atrophy, was observed in PET+/plasma+ compared PET-/plasma- in IP-MS-WashU (right precuneus: estimate = -0.388, $p = 0.011$; left precuneus: estimate = -0.418, $p = 0.004$). In IA-Elc, PET+/plasma+ showed significant lower volume in left precuneus (estimate = -0.335, $p = 0.035$) compared to PET-/plasma-.

Association between PET/plasma groups and cross-sectional cognitive performance

Cross-sectional cognitive performances assessed by MMSE, CDR SB, ADNI MEM, and ADNI EF between PET/plasma groups were




Fig. 1 Scatterplots of distribution and concordance status between amyloid PET and plasma A β 42/40. Distribution and concordance status of IP-MS-WashU (A) and IA-Elc (B). Plasma A β 42/40 z-scores and amyloid PET SUVR values of IP-MS-WashU (orange) and IA-Elc (purple) are fitted using spline model (C). Disagreement number (%) between IP-MS-WashU (blue) and IA-Elc (red) were listed according to PET/plasma groups (D). Agreement cases between IP-MS-WashU and IA-Elc are listed in the middle (purple). Abbreviation: A β amyloid- β , IA-Elc Elecsys immunoassay from Roche Diagnostics, IP-MS-WashU immunoprecipitation followed by mass spectrometry method developed at Washington, PET positron emission tomography.

compared (eTable 3 in Supplement 1). Association analyses showed that PET+/plasma+ showed lower MMSE (estimate = -2.661, $p < 0.001$), higher CDR (estimate = 0.274, $p < 0.001$), higher CDR SB (estimate = 1.713, $p < 0.001$), lower ADNI MEM (estimate = -0.834, $p < 0.001$) and lower ADNI EF scores (estimate = -0.689, $p < 0.001$) compared to PET-/plasma- in IP-MS-WashU (Fig. 4). Moreover, PET+/plasma- was associated with lower ADNI MEM score (estimate = -0.647, $p = 0.037$) than PET-/plasma-. In IA-Elc, PET+/plasma+ was related to significantly poor performances in MMSE (estimate = -2.56, $p < 0.001$), CDR (estimate = 0.287, $p < 0.001$), CDR SB (estimate = 1.676, $p < 0.001$), ADNI MEM (estimate = -0.891, $p < 0.001$), and ADNI EF (estimate = -0.61, $p = 0.002$) compared to the reference group. PET+/plasma- was also associated with significantly poor performances in MMSE (estimate = -2.928, $p = 0.019$), CDR SB (estimate = 1.701, $p = 0.041$), ADNI MEM (estimate = -0.853, $p = 0.014$), and ADNI EF/ (estimate = -1.25, $p < 0.001$) compared to the reference group.

Association between PET/plasma groups and longitudinal cognitive decline

Associations of PET/plasma groups with longitudinal cognitive decline were assessed using linear mixed model. In IP-MS-WashU,

significant interactions between groups and follow-up time were observed in MMSE (estimate = -0.009, $p = 0.001$), CDR (estimate = 0.001, $p = 0.002$), CDR SB (estimate = 0.014, $p < 0.001$) and ADNI MEM (estimate = -0.001, $p = 0.001$) (Fig. 4). In IA-Elc, significant interactions between groups and follow-up time were observed in MMSE (estimate = -0.008, $p = 0.004$), CDR SB (estimate = 0.009, $p = 0.009$), and ADNI MEM (estimate = -0.002, $p = 0.007$). In IA-Elc, PET+/plasma- showed the most rapid cognitive decline compared to other groups, which was not observed in IP-MS-WashU.

Association between PET/plasma groups and PRS

Genetic data generating PRS were available only for 64 participants. Association analyses revealed that PET+/plasma+ was related with higher PRS both in IP-MS-WashU (estimate = 0.856, $p = 0.008$) and IA-Elc (estimate = 0.709, $p = 0.043$) (eFig. 2 in Supplement 1). The median values of PRS showed an ascending pattern across PET-/plasma-, PET-/plasma+, and PET+/plasma. However, PET+/plasma- represented the lowest median value in IP-MS-WashU and the highest in IA-Elc among other PET/plasma groups (eTable 4 in Supplement 1).




Fig. 2 Tau burden according to PET/plasma groups. Association between tau burden assessed by 18F-flortaucipir PET and PET/plasma groups were analyzed using general linear model adjusted for age and sex. Tau deposition in entorhinal, Braak III/IV, and Braak V/VI regions using IP-MS-WashU (A–C) and IA-Elc (D–F). Abbreviation: A β amyloid- β , FTP 18F-flortaucipir, IA-Elc Elecsys immunoassay from Roche Diagnostics, IP-MS-WashU immunoprecipitation followed by mass spectrometry method developed at Washington, PET positron emission tomography, SUVR standardized uptake value ratio.




Fig. 3 Hippocampal and precuneus volume according to PET/plasma groups. Association between brain volume assessed by MRI and PET/plasma groups were analyzed using general linear model adjusted for age, sex, estimated intracranial volume and MRI field strength. Bilateral hippocampal (A, B) and precuneus (C, D) volume according to PET/plasma groups using IP-MS-WashU and bilateral hippocampal (E, F) and precuneus (C, D) volume according to PET/plasma groups using IA-Elc (G, H). Abbreviations: IA-Elc Elecsys immunoassay from Roche Diagnostics, IP-MS-WashU immunoprecipitation followed by mass spectrometry method developed at Washington, Lt left, MRI magnetic resonance image, PET positron emission tomography, Rt right.

DISCUSSION

In this study, we investigated tau burden, brain volume, cross-sectional and longitudinal cognitive function, and PRS between groups defined by amyloid PET and plasma A β 42/40 positivity.

In neuroimaging analysis, PET+/plasma+ were associated with higher tau PET SUVR values in entorhinal, Braak III/IV, and Braak V/VI regions and decreased volume in hippocampus and precuneus compared to PET-/plasma-. While tau burden and hippocampal and precuneus atrophy showed gradual changes across PET-/plasma-, PET-/plasma+, and PET+/plasma+, PET+/plasma- did not follow that order. In cognition analysis, PET+/plasma+ was associated with poor cognitive performance, and gradual decline pattern was shown across PET-/plasma-, PET-/plasma+, PET+/plasma-, and PET+/plasma+. Longitudinal cognitive performance declined in the order of PET-/plasma-, PET-/plasma+, and PET+/plasma+, whereas PET+/plasma- presented inconsistent pattern depending on plasma assays. PRS also showed variability in PET+/plasma-, whereas the ascending tendency was observed in order of PET-/plasma-, PET-/plasma+, and PET+/plasma+.

Overall, PET-/plasma+ showed intermediate changes between PET-/plasma- and PET+/plasma+ in terms of tau burden, hippocampal and precuneus volume, cognitive function, cognitive decline, and genetic risk score. In contrary, PET+/plasma- did not follow a specific order and instead, displayed heterogeneous characteristics with high tau burden in Braak V/VI regions, hippocampal atrophy, rapid cognitive decline, and diverse PRS depending on plasma biomarker assays. Although PET+/plasma- had the smallest proportion among PET/plasma groups within the assay (IP-MS-WashU: 8.3%, IA-Elc: 6.6%), highest disagreement rate was observed between assays (IP-MS-WashU: 80%, IA-Elc: 75%). This indicates that PET+/plasma- comprise heterogeneous characteristics. This might come from concomitant mixed pathology, different disease phenotypes, altered peripheral amyloid clearance capacity affected by other medical condition or medication, and difference in detection technology of plasma

biomarkers. Careful investigation of these individuals might provide more helpful insight on the discordance.

Several previous studies reported the discordance between CSF and PET amyloidopathy positivity, showing abnormal changes in CSF prior to PET [16–20]. The discordant groups are considered to be intermediate between PET-/CSF- and PET+/CSF+ groups [19, 20]. PET-/CSF+ and PET+/CSF- are assumed to be two different A β processing pathways of the early amyloidopathy stages [20, 21]. Plasma biomarker as a fluid biomarker like CSF also undergoes abnormal changes prior to PET [22]. In our study, the PET-/plasma+ group tended to be in the intermediate state between PET-/plasma- and PET+/plasma+ in tau burden, brain volume, clinical course, and PRS, which supports the hypothesis of plasma biomarker being an early biomarker of amyloidopathy prior to PET. On the contrary, PET+/plasma- group was hardly the early stage of amyloidopathy. The difference between PET+/plasma- and PET+/CSF- might be because CSF and plasma A β are two distinct fluid biomarkers from central and peripheral systems. Plasma, which is easily affected by whole body system condition, might have different A β metabolism. Approximate use of two fluid biomarkers should be cautioned and comparison between CSF and plasma biomarkers should be explored in further studies.

Our results demonstrated inter-assays variabilities between IP-MS-WashU and IA-Elc. Regarding the distribution of PET/plasma groups, IA-Elc showed a higher proportion of PET-/plasma+, which was classified as PET-/plasma- measured by IP-MS-WashU (11/16, 59.2%). Moreover, 35.5% of PET-/plasma- (16/45) in IP-MS-WashU was defined as PET-/plasma+ in IA-Elc. This suggests that IA-Elc can detect more plasma amyloid abnormality in the early phase of disease with amyloid PET negativity. In contrast, IP-MS-WashU displayed a more linear association between plasma A β 42/40 and amyloid PET SUVR showing higher amyloid PET positivity predictability. Furthermore, inter-assay differences in tau, brain volume, cognition, and PRS were observed in PET+/plasma-. These discrepancies indicate that two assays might detect individuals




Fig. 4 Cross-sectional cognitive performance and longitudinal cognitive decline according to PET/plasma groups. Association between cross-sectional cognitive performance and PET/plasma groups were analyzed using general linear model adjusted for age, sex, and education levels. MMSE, CDR SB, ADNI MEM, and ADNDI EF scores according to PET/plasma groups using IP-MS-WashU (A–D) and IA-Elc (H–K). Association between longitudinal cognitive changes and PET/plasma groups were analyzed linear mixed model adjusted for age, sex, and education levels. MMSE, CDR SB, and ADNI MEM changes according to PET/plasma groups using IP-MS-WashU (E–G) and IA-Elc (L–N). Abbreviations: ADNI EF Alzheimer’s Disease Neuroimaging Initiative composite score of executive function, ADNI MEM Alzheimer’s Disease Neuroimaging Initiative composite score of memory, CDR SB clinical dementia rating sum of boxes, IA-Elc Elecsys immunoassay from Roche Diagnostics, IP-MS-WashU immunoprecipitation followed by mass spectrometry method developed at Washington, MMSE mini mental state examination, PET positron emission tomography.

with distinct features and can be applied in different disease stages or target subjects according to characteristics of assays. To accomplish this, exploring relation of plasma biomarkers with different AD phenotypes, mixed pathologies, concomitant medical conditions, or medications would be helpful in the future.

Limitations

This study had some limitations. First, the sample size was small and further studies with larger sample size are needed. However, this dataset, namely amyloid PET and plasma measurement of same sample at the same period using various assays, was optimal for the direct comparison between assays. Secondly, we defined thresholds for plasma amyloid positivity in the ADNI cohort based on cut-off values predictive of amyloid PET positivity. Due to the lack of standardized cut-off values for plasma assays, we employed the optimal values that best predict central amyloidopathy. However, it’s important to note that PET/plasma mismatch cases may vary depending on the chosen cut-off values, an issue

that bears significance for both research and clinical applications. To address this, future study with diverse and large cohorts is essential to develop standardized cut-off values for plasma assays. Third, brain amyloidopathy was evaluated with [18 F]florbetapir PET. Central amyloidopathy assessed by amyloid PET with other ligands or CSF measurement might also be meaningful. Fourth, subjects in the study showed relatively good cognitive performance (median CDR 0–0.5). Subjects with diverse cognitive stages might be needed. Fifth, pathological evidence would help better understand the characteristics of groups.

In this study, we found that gradual changes across PET–/plasma–, PET–/plasma+, and PET+/plasma+ regarding tau burden, brain volume, cognitive function, cognitive decline, and PRS could support plasma biomarkers as early biomarker of amyloidopathy prior to amyloid PET. PET+/plasma– showed heterogeneous characteristics. IP-MS-WashU and IA-Elc assays have different features and might be applied distinctively, detecting different target subjects or disease stages.

DATA AVAILABILITY

All demographic, imaging, and genetic data in this study were publicly available and downloaded from the ADNI database (<http://adni.info.org>).

REFERENCES

- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7:263–9.
- Pyun JM, Kang MJ, Ryoo N, Suh J, Youn YC, Park YH, et al. Amyloid metabolism and amyloid-targeting blood-based biomarkers of Alzheimer's disease. *J Alzheimers Dis*. 2020;75:685–96.
- Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid- β 42/40 assays in Alzheimer disease. *JAMA Neurol*. 2021;78:1375–82.
- Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol*. 2022;21:66–77.
- Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β -amyloid. *Ann Neurol*. 2013;74:826–36.
- Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann Neurol*. 2012;72:578–86.
- Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82:239–59.
- Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. *Alzheimers Dement*. 2010;6:212–20.
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189–98.
- Morris JC. The clinical dementia rating (CDR): current version and scoring rules. *Neurology*. 1993;43:2412–4.
- Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain Imaging Behav*. 2012;6:502–16.
- Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. *Brain Imaging Behav*. 2012;6:517–27.
- Euesden J, Lewis CM, O'Reilly PF. PRSice: polygenic risk score software. *Bioinformatics*. 2015;31:1466–8.
- Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet*. 2019;51:404–13.
- 1000 Genomes Project Consortium, Auton A, Brooks LD, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. *Nature*. 2015;526:68–74.
- Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. *JAMA Neurol*. 2017;74:1492–501.
- Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. *Alzheimers Dement*. 2018;14:1460–9.
- Doecke JD, Ward L, Burnham SC, Villemagne VL, Li QX, Collins S, et al. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. *Alzheimers Res Ther*. 2020;12:36.
- de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, et al. Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. *Alzheimers Res Ther*. 2019;11:78.
- Jiang C, Wang Q, Xie S, Chen Z, Fu L, Peng Q, et al. β -Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns. *Brain Commun*. 2022;4:fcac084.
- Sala A, Nordberg A, Rodriguez-Vieitez E, Alzheimer's Disease Neuroimaging Initiative. Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- β positivity. *Mol Psychiatry*. 2021;26:5864–74.

- Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Mol Med*. 2019;11:e11170.

ACKNOWLEDGEMENTS

Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This work is also supported by grant 02-2016-0005 from Seoul National University Bundang Hospital, and by the Soonchunhyang University Research Fund.

AUTHOR CONTRIBUTIONS

J-MP, YHP, YCY, KHS, and SK contributed to conception and design of the study; J-MP, KHS, MJK, J-WJ, JY, KN, and SK contributed to the acquisition and analysis of data; all authors contributed to drafting the text or preparing the figures.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41398-024-02766-6>.

Correspondence and requests for materials should be addressed to SangYun Kim.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE

Michael W. Weiner⁹, Paul Aisen¹⁰, Ronald Petersen¹¹, Clifford R. Jack Jr¹¹, William Jagust¹², John Q. Trojanowki¹³, Arthur W. Toga¹⁰, Laurel Beckett¹⁴, Robert C. Green¹⁵, Andrew J. Saykin⁷, John Morris¹⁶, Leslie M. Shaw¹³, Greg Sorensen¹⁷, Maria Carrillo¹⁸, Lew Kuller¹⁹, Marc Raichle¹⁶, Steven Paul²⁰, Peter Davies²¹, Howard Fillit²², Franz Hefti²³, David Holtzman¹⁶, M. Marcel Mesulam²⁴, William Potter²⁵, Peter Snyder²⁶, James Hendrix¹⁸, Aparna Vasanthakumar²⁷, Tom Montine²⁸, Michael Rafii¹⁰, Tiffany Chow¹⁰, Rema Raman¹⁰, Gustavo Jimenez¹⁰, Michael Donohue¹⁰, Devon Gessert¹⁰, Kelly Harless¹⁰, Jennifer Salazar¹⁰, Yuliana Cabrera¹⁰, Sarah Walter¹⁰, Lindsey Hergesheimer¹⁰, Danielle Harvey¹⁴, Michael Donohue²⁹, Matthew Bernstein¹¹, Nick Fox³⁰, Paul Thompson³¹, Norbert Schuff⁹, Charles DeCarli¹⁴, Bret Borowski¹¹, Jeff Gunter¹¹, Matt Senjem¹¹, Prashanthi Vemuri¹¹, David Jones¹¹, Kejal Kantarci¹¹, Chad Ward¹¹, Robert A. Koeppe³², Norm Foster³³, Eric M. Reiman³⁴, Kewei Chen³⁴, Chet Mathis¹⁹, Susan Landau¹², Nigel J. Cairns¹⁶, Erin Franklin¹⁶, Virginia Lee¹³, Magdalena Korecka¹³, Michal Figurski¹³, Karen Crawford¹⁰, Scott Neu¹⁰, Tatiana M. Foroud³⁵, Steven Potkin³⁶, Li Shen³⁶, Kelley Faber³⁶, Sungeun Kim³⁶, Marilyn Albert³⁷, Richard Frank³⁸, John Hsiao³⁹ and Zaven Khachaturian⁴⁰

⁹University of California San Francisco, San Francisco, CA, USA. ¹⁰University of Southern California, Los Angeles, CA, USA. ¹¹Mayo Clinic, Rochester, MN, USA. ¹²University of California Berkeley, Berkeley, CA, USA. ¹³University of Pennsylvania, Philadelphia, PA, USA. ¹⁴University of California Davis, Davis, CA, USA. ¹⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA. ¹⁶Washington University St. Louis, St. Louis, MO, USA. ¹⁷Siemens, Charlotte, NC, USA. ¹⁸Alzheimer's Association, Chicago, IL, USA. ¹⁹University of Pittsburgh, Pittsburgh, PA, USA. ²⁰Cornell University, Ithaca, NY, USA. ²¹Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA. ²²AD Drug Discovery Foundation, New York, NY, USA. ²³Acumen Pharmaceuticals, Charlottesville, VA, USA. ²⁴Northwestern University, Evanston, IL, USA. ²⁵National Institute of Mental Health, Bethesda, MD, USA. ²⁶Brown University, Providence, RI, USA. ²⁷AbbVie, JD Hoofddorp, Amsterdam, Netherlands. ²⁸University of Washington, Seattle, WA, USA. ²⁹University of California San Diego, La Jolla, CA, USA. ³⁰University of London, London, England, UK. ³¹UCLA School of Medicine, Los Angeles, CA, USA. ³²University of Michigan, Ann Arbor, MI, USA. ³³University of Utah, Salt Lake City, UT, USA. ³⁴Banner Alzheimer's Institute, Phoenix, AZ, USA. ³⁵Indiana University, Bloomington, IN, USA. ³⁶University of California Irvine, Irvine, CA, USA. ³⁷Johns Hopkins University, Baltimore, MD, USA. ³⁸Richard Frank Consulting, Gainesville, FL, USA. ³⁹National Institute of Aging, Bethesda, MD, USA. ⁴⁰Prevent Alzheimer's Disease 2020, Bethesda, MD, USA.